Key result
Selective estrogen-receptor modulators exert tissue-specific agonist and antagonist effects in postmenopausal women.
Answers are grounded in this paper and cite their sources.
Selective estrogen-receptor modulators are nonsteroidal compounds that act as estrogen agonists in some tissues and as estrogen antagonists in others. Thus, they are uniquely suited for postmenopausal women. An ideal selective estrogen-receptor modulator would offer postmenopausal women the benefits of estrogen therapy (i.e., a reduced risk of fracture, urologic and vaginal atrophy, and hot flushes) without the risks (i.e., an increased risk of breast cancer, endometrial cancer, coronary heart disease, stroke, and venous thromboembolic events).Tamoxifen and raloxifene, the two selective estrogen-receptor modulators currently marketed for postmenopausal women in the United States, offer both benefits and drawbacks. Tamoxifen is associated . . .
No takes yet. Share an insight, caveat, or question.
Carolyn Black Becker (2010) conducted an editorial in Osteoporosis in postmenopausal women. Selective estrogen-receptor modulators (SERMs) was evaluated. Selective estrogen-receptor modulators act as tissue-specific estrogen agonists and antagonists in postmenopausal women, with 2 currently marketed in the United States (tamoxifen and raloxifene).
Synapse has enriched 10 related papers. Consider them for comparative context: